BlueRun Ventures Continues to Back Ruisi Technology in 100 Million RMB Series A+ Round | BlueRun Ventures

Recently, Revo Vision Technology announced the completion of its Series A+ funding round, raising over 100 million RMB. The round was led by Sinovation Ventures, with follow-on investment from Botanee, and continued support from existing shareholders Yaojin Capital and BlueRun Ventures.

BlueRun Ventures led Revo Vision's Series A round.

BlueRun Ventures stated: The Revo Vision team possesses a rare interdisciplinary background, with top talent spanning XR optical design, myopia prevention science, innovative AI algorithms, digital therapeutics, clinical trials, and regulatory certification. Grounded in the underlying mechanisms of myopia formation, the team has prioritized efficacy from day one, originally defining an entirely new product category while continuously optimizing user experience and iterating on product performance. We are highly optimistic about the trend toward digitalized, personalized myopia prevention and control.

In recent years, shifts in lifestyle and learning habits have gradually increased Chinese adolescents' reliance on electronic devices, with a corresponding rise in visual burden. In 2021, the overall myopia rate among Chinese children and adolescents reached 52.6%, placing China among the highest globally. Myopia rates among middle and high school students have risen to over 70% and 80%, respectively. Myopia has become one of the most significant health risks for Chinese children and adolescents, with high myopia carrying further risk of additional eye diseases.

In response, national policy has strongly supported adolescent myopia screening and prevention, elevating child and adolescent myopia control to a strategic government priority. Guided by national policy and driven by strong market demand, frontier technologies in the eye care and vision field have continuously evolved, and the range of myopia prevention products has steadily expanded — with mainstream approaches all experiencing rapid growth.

Among myopia prevention methods, the ideal product profile should feature: 1) efficacy; 2) safety; 3) high compliance; 4) ease of use; 5) evidence-based validation; 6) personalization.

Revo Vision has creatively developed a proprietary digital myopia prevention pathway, launching a comprehensive solution for full-lifecycle eye health management and child/adolescent myopia control. The company's core product, the Revo Vision Far-Vision Light Screen, uses digital display devices as its载体, achieving digitalized and personalized defocus through proprietary optical hardware and software technology. By integrating into the high-frequency visual scenarios of children's daily lives, it seamlessly transforms electronic device usage into an eye protection process, delaying the onset and progression of myopia in adolescents. It provides a targeted, integrated solution combining learning, entertainment, and myopia prevention. Compared to traditional approaches, it eliminates complex fitting procedures and dedicated training time, significantly enhancing user experience, and creating a more personalized, higher-compliance, and easier-to-use myopia prevention solution. Early clinical trial data has already shown promising efficacy results.

Revo Vision remains committed to its original mission, placing clinical safety and efficacy as its top priorities. Proceeds from this round will primarily fund multi-center GCP clinical trials and regulatory certification for multiple products nationwide, including applications for Class II, Class III, and innovative medical device certifications. The company will continue strengthening its key technical moats and optimizing product performance and efficacy. It will increase R&D investment to explore the cutting edge of myopia prevention — digitalized "personalized defocus solutions" — further enhancing the effect of delaying myopia progression and strengthening the core competitiveness of future products.

As the creator and leader of far-vision technology, Revo Vision is resolutely advancing the innovation and upgrade of digital myopia prevention technology and broader myopia management solutions. It aims to continuously refine its products through technological revolution, providing innovative and effective "digital therapeutics" for myopia management, making intelligent eye protection ubiquitous, redefining myopia management through innovative technology products, truly empowering China's eye care and vision industry, promising the public brightness and healthcare warmth.

Revo Vision founder Jun Yao stated: Revo Vision will attract more specialized R&D talent, increase R&D investment, and accelerate the scaled development of the Revo Vision Far-Vision Light Screen and digital diagnostic/therapeutic products, as well as expand into international overseas markets. Revo Vision will remain focused on exploring frontier myopia prevention technologies, continuously launching more advanced technology products, truly achieving "thousand people, thousand eyes" personalized customization, obtaining better myopia prevention outcomes, and helping more children and adolescents achieve visual freedom.

👇 Seeking funding or partnership? Long-press the QR code below 👇 Add BlueRun's "Little Chi" on WeChat to connect with us directly.

▶ More Content ◀

Founded in Silicon Valley, BlueRun Ventures was established in 2005 as a venture capital firm focused on early-stage startups.

Currently, BlueRun Ventures manages multiple USD and RMB dual-currency funds in China, with assets under management exceeding 15 billion RMB, making it one of the largest early-stage funds domestically. The firm invests primarily at Pre-A and Series A stages, covering hard tech and innovative interaction, enterprise technology, new consumer, and healthcare sectors. It has cumulatively invested in over 150 startups, including Li Auto, Waterdrop, QingCloud, Guazi.com, Qudian, Songguo Mobility, Ganji.com, Energy Monster, Yuntu Semiconductor, Machenike, CloudSaints Intelligence, Anxin Netshield, and BioMap.

BlueRun Ventures has been ranked #1 on Zero2IPO's "China Top 30 Early-Stage Investment Institutions" and ChinaVenture's "China Best Early-Stage Venture Capital Institutions TOP30," and was named among Preqin's Top 10 VC Fund Managers Globally for Sustained High Returns.

Additionally, BlueRun Ventures has repeatedly received honors from Forbes China, 36Kr, Cyzone, Caixin Media, CBNweekly, Jiemian, and other media outlets, including "China's Best Early-Stage Institution of the Year," "China's Top Venture Capital Firm," "Most Entrepreneur-Friendly Early-Stage Institution of the Year," and "Most Influential Early-Stage Institution of the Year."